3 very different biotechs all file for the same IPO goal: A big raise on Nasdaq Rejuvenate Bio banks $10M to advance gene therapy for aging in humans and dogs Adagio raises a monster $336M round for bespoke COVID-19 drug battle Sponsored: Why Integrated Partners are Critical to Cell and Gene Therapy Success Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact Lyndra's ultralong-acting pill shows promise in schizophrenia phase 2, teeing up pivotal trial Epizyme's EZH2 blocker boosts immuno-oncology response in prostate cancer models The top 10 ad spenders in Big Pharma for 2020 Zymeworks' first CMO moves on as lead cancer candidate heads for commercialization Could this common heart drug defeat obesity by preventing inflammation? Featured Story | By Ben Adams A stem cell biotech, a liver disease specialist and a gene therapy company have all got in the conga line for the biotech IPO boom. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Rejuvenate Bio raised more than $10 million in its series A round to propel its gene therapy toward the market for the treatment of heart disease in dogs and toward the clinic for the treatment of aging-related conditions in humans, including heart failure, kidney failure, Type 2 diabetes and obesity. read more By Ben Adams Adagio Therapeutics has nabbed a massive $336 million series C from a who’s who of investors as it more than triples its previous funding drive last year. read more Sponsored By: Catalent Cell & Gene Therapy Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, viral vector production and quality requirements. read more By Ben Adams Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19. read more By Amirah Al Idrus In a phase 2 study, patients taking Lyndra Therapeutics’ once-weekly schizophrenia pill, LYN-005, quickly reached therapeutic levels of the drug, according to data presented virtually Sunday at the Congress of the Schizophrenia International Research Society. The study pitted Lyndra’s treatment, an ultralong-acting version of the antipsychotic risperidone, against immediate-release risperidone in 34 patients diagnosed with schizophrenia or schizoaffective disorder. read more By Arlene Weintraub Cedars-Sinai Cancer researchers showed in preclinical models of prostate cancer that blocking the enzyme EZH2 reduces resistance to immune-boosting checkpoint inhibitors—and they did it with the help of Epizyme, which won FDA approval for the first EZH2 blocker last year. They're now planning a clinical trial. read more By Beth Snyder Bulik Even as other industries slashed ad budgets, pharma advertisers continued to spend on TV and digital especially—reaching a total of $6.6 billion in 2020. read more By Annalee Armstrong Zymeworks CMO Diana Hausman, M.D., will pass the torch to Neil Josephson, M.D., who currently oversees the Canadian biotechnology company’s global clinical studies. read more By Arlene Weintraub Spanish researchers discovered that digoxin, a drug used to treat heart failure and rhythm disorders, could be an effective strategy for treating obesity. The drug tamped down an inflammatory molecule called interleukin 17A (IL-17A), in mouse models of obesity, promoting weight loss, they reported. read more Resources Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Pharma PR & Communications Virtual Summit April 20–22, 2021 | Virtual Event Medical Affairs Strategic Summit (MASS) Virtual May 5-7, 2021 | Virtual Event TMF Virtual Summit May 18-20, 2021 | Virtual Event Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST | 